MaxCyte Director Sells Shares Amid Active Trading
Company Announcements

MaxCyte Director Sells Shares Amid Active Trading

MaxCyte (MXCT) has released an update.

Don't Miss out on Research Tools:

MaxCyte, Inc., a prominent cell-engineering company, announced that Non-Executive Director Stanley Erck exercised options and sold 47,689 shares of the company’s common stock. The shares were sold at prices ranging from $3.610 to $3.755, representing 8.04% of his total equity and option holdings. Following the transaction, Erck retains 247,751 shares, highlighting active insider trading activity within MaxCyte.

For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMaxCyte Weighs Delisting from AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead
TipRanks UK Auto-Generated NewsdeskMaxCyte’s Revenue Grows and Strategic Moves Unveiled
TipRanks UK Auto-Generated NewsdeskMaxCyte Files Quarterly Report, Highlights Financial Progress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App